Profile data is unavailable for this security.
About the company
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-53.45m
- Incorporated2021
- Employees42.00
- LocationSurrozen Inc171 Oyster Point Blvd, Suite 400SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 475-2820
- Fax+1 (302) 655-5049
- Websitehttps://www.surrozen.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aeon Biopharma Inc | 0.00 | -305.52m | 29.64m | 5.00 | -- | -- | -- | -- | -8.40 | -8.40 | 0.00 | -0.7144 | 0.00 | -- | -- | 0.00 | -6,646.10 | -- | -- | -- | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Mink Therapeutics Inc | 0.00 | -17.09m | 29.66m | 31.00 | -- | -- | -- | -- | -0.4891 | -0.4891 | 0.00 | -0.4202 | 0.00 | -- | -- | 0.00 | -152.35 | -- | -4,151.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 29.75m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Grace Therapeutics, Inc | 0.00 | -11.45m | 29.91m | 32.00 | -- | 0.5039 | -- | -- | -1.22 | -1.22 | 0.00 | 5.85 | 0.00 | -- | -- | -- | -16.04 | -31.68 | -16.57 | -33.95 | -- | -- | -- | -56,271.43 | -- | -37.80 | 0.00 | -- | -- | -- | 69.71 | -- | -47.16 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 30.22m | 4.00 | -- | 8.68 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 30.78m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Longeveron Inc | 1.23m | -27.90m | 31.59m | 23.00 | -- | 1.42 | -- | 25.70 | -8.75 | -8.75 | 0.3641 | 1.55 | 0.0674 | -- | 7.83 | 53,434.78 | -101.98 | -63.15 | -127.46 | -75.68 | 58.99 | 33.70 | -1,513.83 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Iterum Therapeutics PLC | 0.00 | -28.34m | 31.79m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.658 | 0.00 | -- | -- | 0.00 | -86.93 | -118.12 | -150.76 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 2.06 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| SAB Biotherapeutics Inc | 2.78m | -40.32m | 32.39m | 57.00 | -- | 0.7024 | -- | 11.65 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.42m | 163.00 | -- | 0.1589 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| FibroGen Inc | 173.82m | -168.32m | 32.43m | 486.00 | -- | -- | -- | 0.1866 | -1.71 | -1.71 | 1.76 | -2.31 | 0.4301 | 1.22 | 44.10 | 357,644.00 | -42.40 | -30.62 | -89.79 | -42.31 | 76.65 | 93.52 | -98.60 | -119.08 | 1.24 | -12.47 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Aligos Therapeutics Inc | 7.97m | -75.74m | 32.57m | 68.00 | -- | 0.9524 | -- | 4.09 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Surrozen Inc | 0.00 | -53.45m | 32.60m | 42.00 | -- | 5.38 | -- | -- | -21.74 | -21.74 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -98.01 | -- | -110.62 | -- | -- | -- | -- | -- | -- | -2.05 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -64.66m | 32.83m | 41.00 | -- | 0.3336 | -- | -- | -2.26 | -2.26 | 0.00 | 3.30 | 0.00 | -- | -- | 0.00 | -62.35 | -- | -69.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Impact Biomedical Inc | 0.00 | -4.25m | 33.34m | 1.00 | -- | 1.43 | -- | -- | -0.3694 | -0.3694 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -9.59 | -- | -15.04 | -- | -- | -- | -- | -- | -- | -5.12 | 0.3377 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Dyadic International Inc | 1.80m | -7.74m | 33.60m | 7.00 | -- | 10.61 | -- | 18.63 | -0.2675 | -0.2675 | 0.0624 | 0.1075 | 0.1662 | -- | 3.55 | 257,731.40 | -71.33 | -36.82 | -87.19 | -39.85 | 50.01 | 22.47 | -429.07 | -410.16 | -- | -- | 0.6324 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Surrozen Inc's reporting currency: US Dollar USD
42.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| StemPoint Capital LPas of 31 Oct 2024 | 293.12k | 9.14% |
| RA Capital Management LPas of 30 Jun 2024 | 282.58k | 8.82% |
| Armistice Capital LLCas of 30 Jun 2024 | 190.00k | 5.93% |
| Nantahala Capital Management LLCas of 30 Jun 2024 | 187.21k | 5.84% |
| Euclidean Capital LLCas of 30 Jun 2024 | 87.70k | 2.74% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Sep 2024 | 79.36k | 2.48% |
| Stonepine Capital Management LLCas of 30 Jun 2024 | 66.08k | 2.06% |
| Heights Capital Management, Inc.as of 30 Jun 2024 | 64.91k | 2.03% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 60.41k | 1.88% |
| ArrowMark Colorado Holdings LLCas of 30 Jun 2024 | 55.12k | 1.72% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
